Fresenius Kabi Launches Single-Needle Option for the Amicus® Extracorporeal Photopheresis Protocol
Fresenius Kabi today announced the availability of a single-needle venous access option for the Amicus® Extracorporeal Photopheresis (ECP) System at the 49th annual meeting of the European Society for Blood and Marrow Transplantation (EBMT).
Fresenius Kabi is a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition.
The Amicus Blue System with online ECP was launched in Europe in 2019 with double-needle venous access only. The update announced today includes new software v6.1 for the Amicus Separator, new software v2.1 for the Phelix Photoactivation Device and a new single-use disposable kit that can be configured for single or double-needle venous access. The system also allows clinicians to switch between single and double-needle access at any time during the procedure.
“We are thrilled to enable the single-needle option for the Amicus Blue ECP system, which will allow physicians to treat patients with limited venous access. This builds on our Amicus Blue vision to provide a versatile, multi-procedural instrument to support patients’ individual needs,” said Christian Hauer, President Fresenius Kabi MedTech.
The Amicus ECP System has obtained CE mark for the indication of CTCL in the palliative treatment of the skin manifestations of cutaneous T-cell lymphoma (CTCL) that is unresponsive to other forms of treatment. The Amicus ECP System is CE marked in compliance with the applicable requirements of the Medical Device Regulation (EU) 2017/745 and includes:
- Amicus Separator
- Phelix Photoactivation Device
- Amicus ECP Apheresis Kits
Amicus Separator is also cleared in Europe and the United States for therapeutic plasma exchange (TPE), red blood cell exchange (RBCx), mononuclear cell (MNC) collection and platelet collection. The Amicus ECP System is not cleared for use in the U.S.
Not all products listed are available or approved for sale in all countries. Contact your local Fresenius Kabi representative for additional information and product availability. Refer to the Amicus Separator Operator’s Manual and Phelix Photoactivation Device Operator’s Manual for a complete list of warnings and precautions associated with the use of these products.
About Extracorporeal Photopheresis
Extracorporeal photopheresis or ECP is a leukapheresis-based therapeutic procedure. The technology is currently approved for the treatment of cutaneous T-cell lymphoma (CTCL). Literature shows that it has also been used for graft versus host disease (GvHD) following bone marrow or stem cell transplant, the rejection of solid organ transplants, and autoimmune diseases where cell-mediated mechanisms are dominant.
An online ECP procedure involves collection of mononuclear cells from the patient, treatment of collected cells with a light sensitive drug, 8-methoxypsoralen and exposure of cells to UV-A light, followed by the reinfusion of treated cells back to the patient. After reinfusion, the treated cells become apoptotic and are believed to be taken up by antigen presenting cells resulting in an immune response. The online ECP process combines cell separation and photoactivation into a single, sterile circuit reducing the risk of infection and cross-contamination.
About Cutaneous T-cell Lymphoma
Cutaneous T-cell lymphomas are a heterogenous group of T-cell lymphoproliferative disorders involving the skin, the most common variants classified as Mycosis Fungoides (MF) or Sézary Syndrome (SS). Patients may experience itchy, scaly patches or plaques of the skin. As the disease progresses, some patients may experience growth of nodular lesions and large tumors, and internal organ involvement. Treatment is palliative, with the aim to induce long-term remissions and improve patient quality of life.
About Fresenius Kabi
Fresenius Kabi (www.fresenius-kabi.com) is a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition. The company’s products and services are used to help care for critically and chronically ill patients. The company’s global headquarters is in Bad Homburg, Germany.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230423005002/en/
Contact information
Dolores Juarez
+49 152 563 86727
dolores.juarez@fresenius-kabi.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Leon and SkyAccess Announce Official Integration to Automate Empty Leg Listings for Charter Operators Across Europe20.1.2026 15:24:00 EET | Press release
SkyAccess, a real-time empty leg flight marketplace that aggregates private jet repositioning flights from a network of certified operators, and Leon Software, a cloud-based aviation management software platform used by charter operators worldwide, today announced an official integration that enables Leon charter operators to automatically list eligible empty leg and repositioning flights on the SkyAccess empty-leg marketplace. Meeting Growing Demand for Empty Leg Flights in Europe The announcement comes as interest in empty leg flights continues to grow across Europe, particularly on short-haul routes between major business and leisure hubs. Travelers are increasingly seeking flexible, one-way private jet options and more transparent access to repositioning flights. “Empty legs move quickly, and speed matters,” said Paweł Szmagaj, CTO of Leon Software. “With the Leon Software–SkyAccess integration, operators can share up-to-date availability with the market faster, while maintaining f
Colgate-Palmolive and WHO Foundation Announce Global Partnership on Oral Health20.1.2026 15:00:00 EET | Press release
Today, Colgate-Palmolive announced a new multi-year collaboration with the WHO Foundation to support the World Health Organization's work on oral health. The four-year funding commitment will help expand oral health education, support integration of oral health into national health systems, and raise awareness of oral health as a public health priority. This initiative builds on Colgate’s commitment to providing communities with oral health education and resources. The Company recently announced that the Colgate Bright Smiles, Bright Futures® program has reached approximately two billion children and their families around the world since 1991 with oral health education. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260120050760/en/ “At Colgate-Palmolive, we are driven by our purpose to reimagine a healthier future for all – and to make more smiles. We’re launching this collaboration with the WHO Foundation given its unique
FGS Global Launches AI Advisory Practice and Acquires Threat Intelligence Firm Memetica20.1.2026 15:00:00 EET | Press release
FGS Global, the world's leading stakeholder strategy firm, today announced the launch of its AI Advisory practice and the acquisition of Memetica, a specialist technology consultancy in AI-driven threat detection and mitigation across social, dark web and fringe platforms. The new practice sits within FGS Global's recently formed AI and Innovation group led by Aaron Kwittken, Global Head of AI and Innovation. The AI Advisory practice builds on and consolidates FGS Global's deliberate, years-long investment in AI capabilities to support surging client demand for strategic and practical guidance on leveraging AI and emerging technologies to enhance communications efficacy, reputational defense and operational efficiencies. This critical work is supported by a global team of more than 200 strategists, analysts, engineers, developers, designers and data scientists across AI strategy, digital influence, campaigns, earned, paid and owned media, influencer engagement, special situations and c
CAS IP Finder Expands Intellectual Property Search Access Across Organizations20.1.2026 15:00:00 EET | Press release
CAS, a division of the American Chemical Society specializing in scientific knowledge management, announces complete functionality for CAS IP Finder™, powered by STN™. CAS STNext® customers can now access the full intellectual property search solution across all search methods, expanded content collections, and advanced analysis tools. Patent volume continues to grow, and scientific disciplines are increasingly interconnected, making intellectual property research more complex and increasing the risk of missed prior art. Organizations traditionally chose between empowering specialized searchers with comprehensive tools or providing limited capabilities to broader teams. CAS IP Finder eliminates that compromise by providing flexible access points that connect users of all experience levels to curated content and precise search tools. "As scientific and patent data grow in complexity, organizations need IP search solutions that enable access across entire teams," said Manuel Guzman, Pres
Parse Biosciences and Graph Therapeutics Partner to Build Large Functional Immune Perturbation Atlas20.1.2026 15:00:00 EET | Press release
Parse Biosciences and Graph Therapeutics (Graph) today announced a strategic partnership to create one of the largest and most comprehensive immune cell perturbation atlases. The collaboration will leverage Graph's lab-in-the-loop platform with Parse's GigaLab to profile hundreds of millions of cells from patients with immune diseases under systematic perturbation, making the immune system’s highly dynamic behavior accessible to AI-first drug discovery and development. This endeavor derisks and speeds up the development of new curative therapies for patients with immune-mediated diseases. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260120419953/en/ Autoimmune and immune-mediated diseases are driven by context- and patient-specific immune cell population responses, making it difficult for drug developers to identify drug targets and predict clinical outcomes. The partnership between Graph and Parse addresses this challenge
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom